Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$0.78 USD

0.78
702,130

0.00 (-0.11%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $0.78 0.00 (-0.56%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AMRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Amarin Corporation PLC [AMRN]

Reports for Purchase

Showing records 301 - 320 ( 361 total )

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 301

07/25/2012

Company Report

Pages: 4

Further Patent Strength Ahead of Tomorrow''s PDUFA

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 302

07/24/2012

Company Report

Pages: 4

ANCHOR Results Published; See Thursday Approval and Looking to Next Move

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 303

07/24/2012

Daily Note

Pages: 19

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 304

07/23/2012

Company Report

Pages: 7

See Thursday Approval, but "What''s Next?" is Very Important; Takeout?

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 305

07/19/2012

Daily Note

Pages: 4

Continue to Expect High Probability of AMR101 Approval but View Website and Label "Leak" as Inconclusive

Provider: WEDBUSH SECURITIES INC.

Analyst: FELT A

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 306

07/13/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 307

07/12/2012

Daily Note

Pages: 5

New ANCHOR Data Surfaces in Patent Application; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: FELT A

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 308

07/06/2012

Industry Report

Pages: 5

LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of July 8

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 309

07/02/2012

Daily Note

Pages: 6

885 Allowance with ''889 On Deck; AMR101 Exclusivity and Valuation Impact; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: FELT A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 310

07/02/2012

Company Report

Pages: 4

Additional Patent Win with ''885 Allowance; Expect AMR101 Approval

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 311

06/29/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 312

06/28/2012

Daily Note

Pages: 11

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 313

06/27/2012

Company Report

Pages: 4

Key ''889 Patent Likely Allowed Soon; Expect July Approval

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 314

06/22/2012

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of June 24

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 315

05/30/2012

Daily Note

Pages: 13

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 316

05/29/2012

Company Report

Pages: 4

''598 Patent Issued, as Expected; Expect Full Approval in July

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 317

05/29/2012

Daily Note

Pages: 4

Another Overhang Falls as Pronova/GSK Prevail in Generic Lovaza Trial; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: FELT A

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 318

05/17/2012

Daily Note

Pages: 4

Update on AMR101 ''889 Patent Application; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: FELT A

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 319

05/11/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 13

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 320

05/09/2012

Daily Note

Pages: 25

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party